Focused On-demand Library for Aminopeptidase O

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

PARTNER
Receptor.AI
 
UPACC
Q8N6M6

UPID:
AMPO_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q8N6M6; Q5T9B1; Q5T9B3; Q5T9B4; Q8WUL6; Q96M23; Q96SS1

BACKGROUND:
Aminopeptidase O, with its recommended name and pivotal function in the hydrolysis of amino acids from peptides or proteins, is integral to the regulation of protein turnover and homeostasis. Its activity influences cellular processes by modulating the availability of amino acids for protein synthesis or degradation.

THERAPEUTIC SIGNIFICANCE:
Given its association with Dystonia 31, a disorder marked by sustained involuntary muscle contractions, Aminopeptidase O represents a promising avenue for research into novel treatments. Exploring the enzymatic mechanisms of Aminopeptidase O could lead to breakthroughs in therapeutic interventions for those affected by this and potentially other related neurological disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.